Special: This Hidden Stock Under $5 Holds Tech World Hostage



FATE: Fate Therapeutics, Inc. is a Sell

The current rating for FATE is 35, which is 43% below its historic median rating of 50. This indicates higher risk than normal.

The rating is currently showing a lower than normal reading, suggesting risk levels could be higher than normal and additional caution is advised.